HCV therapy and risk of liver cancer recurrence: who to treat?

被引：8
|
作者：
Colombo, Massimo [1 ,2 ,3 ]
Boccaccio, Vincenzo [1 ,2 ,3 ]
机构：
[1] Humanitas Hosp, Ctr Translat Res Hepatol, Rozzano, Italy
[2] Humanitas Clin & Res Ctr, Rozzano, Italy
[3] Humanitas Hosp, Dept Med, Rozzano, Italy
来源：
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY | 2018年 / 15卷 / 07期
关键词：
D O I：
10.1038/s41575-018-0018-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Recurrence of hepatocellular carcinoma after resection or ablation with curative intent is common and not prevented by direct-acting antiviral agent (DAA) therapy for hepatitis C. Owing to multiple methodological inconsistencies, available studies fail to answer whether DAA therapy anticipated risk of severe tumour recurrence: a prospective randomized study might serve the purpose. © 2018 Macmillan Publishers Ltd., part of Springer Nature.
引用
收藏
页码：392 / 394
页数：3
相关论文
共 50 条
  • [1] HCV therapy and risk of liver cancer recurrence: who to treat?
    Massimo Colombo
    Vincenzo Boccaccio
    Nature Reviews Gastroenterology & Hepatology, 2018, 15 : 392 - 393
  • [2] Safety and Efficacy of Telaprevir-Based Triple Therapy to Treat HCV Recurrence Post-Liver Transplantation
    Singh, Tavankit
    Singh, Gurshawn
    Fung, John J.
    Zein, Nizar N.
    Eghtesad, Bijan
    Alkhouri, Naim
    GASTROENTEROLOGY, 2014, 146 (05) : S980 - S980
  • [3] PRO view: treat to prevent recurrence of HCV
    Everson, Gregory T.
    LIVER INTERNATIONAL, 2015, 35 (01) : 5 - 6
  • [4] Long-term maintenance of SVR in difficult-to-treat HCV genotypes in liver transplant recipients with HCV recurrence
    Ponziani, Francesca Romana
    Milani, Alessandro
    Gasbarrini, Antonio
    Zaccaria, Raffaella
    Vigano, Raffaella
    Iemmolo, Rosa Maria
    Donato, Maria F.
    Rendina, Maria
    Toniutto, Pierluigi
    Pasulo, Luisa
    Morelli, Maria Cristina
    Burra, Patrizia
    Miglioresi, Lucia
    Merli, Manuela
    Di Paolo, Daniele
    Fagiuoli, Stefano
    Pompili, Maurizio
    HEPATOLOGY, 2012, 56 : 1004A - 1004A
  • [5] A closing chapter - therapy of HCV genotype III recurrence in liver transplants
    Teegen, Eva
    Globke, Brigitta
    Schott, Eckart
    Pratschke, Johann
    Eurich, Dennis
    TRANSPLANTATION, 2016, 100 (07) : S275 - S275
  • [6] A CLOSING CHAPTER - THERAPY OF HCV GENOTYPE III RECURRENCE IN LIVER TRANSPLANTS
    Teegen, E. M.
    Globke, B.
    Schott, E.
    Pratschke, J.
    Eurich, D.
    TRANSPLANT INTERNATIONAL, 2016, 29 : 21 - 21
  • [7] Risk factors influencing HCV recurrence after liver transplantation.
    Russo, FP
    Galligioni, A
    Piaserico, S
    Fagiuoli, S
    Cillo, U
    Zanus, G
    Naccarato, R
    Burra, P
    HEPATOLOGY, 2002, 36 (04) : 656A - 656A
  • [8] Risk factors for accelerated HCV recurrence after liver transplantation.
    Radenne, S
    Bizollon, T
    Ducerf, C
    Chevallier, M
    Baulieux, J
    Trepo, C
    GASTROENTEROLOGY, 1997, 112 (04) : A1362 - A1362
  • [9] Antiviral therapy in HCV decompensated cirrhosis: To treat or not to treat?
    Navasa, Miquel
    Forns, Xavier
    JOURNAL OF HEPATOLOGY, 2007, 46 (02) : 185 - 188
  • [10] HCV therapy: Treat now or wait?
    Cohn A.
    Aronsohn A.
    Current Hepatitis Reports, 2013, 12 (1) : 7 - 12
12345